The Company, based in Menlo Park, has developed a novel transcatheter implant called the PARACHUTETM Ventricular Partitioning Device (PARACHUTETM). The PARACHUTETM intends to treat heart failure resulting from a heart attack or myocardial infarction in millions of patients worldwide by improving overall cardiac function.
Current Team (7)Update
Past Team (4)Update
Funding Rounds (3) - $71MUpdate
Board Members and Advisors (8)Update
Panorama Capital invests in passionate entrepreneurs building leading companies in life sciences...
Health-Care Focused VC Firm
Venture capital Firm
J.P. Morgan Partners, LLC (JPMP) is a private equity division of JPMorgan Chase & Co. (NYSE:...
U.S. Venture Partners (USVP) is a leading Silicon valley-based venture capital firm, helping...
925 Hamilton Avenue,
Menlo Park, CA 94025